Atezolizumab Combo Demonstrates Survival Benefit for ES-SCLC in Maintenance Phase
January 31st 2021January 31, 2021 - The latest data from the IMpower133 trial shows that maintenance therapy with atezolizumab plus carboplatin and etoposide improves overall survival and progression-free survival for patients with extensive stage small cell lung cancer.
Neoadjuvant Atezolizumab Elicits Impressive Responses in Resectable NSCLC
January 30, 2021 - Neoadjuvant atezolizumab followed by surgery resulted in a major pathologic response in 21% of patients with resectable stage IB-IIIB non–small cell lung cancer, as well as significant surgical outcomes with a high rate of R0 resection.
HRQoL Maintained With Adjuvant Osimertinib in EGFR+ NSCLC
January 30th 2021January 29, 2021 - Health-related quality of life was maintained for patients with EGFR-positive non–small cell lung cancer who received treatment with adjuvant osimertinib versus placebo, with no clinically meaningful differences noted between study arms.
Pembrolizumab/Ipilimumab Combo Does Not Improve Survival, Shows Higher Toxicity in PD-L1+ NSCLC
January 29, 2021 - Pembrolizumab plus ipilimumab did not improve survival and had higher rates of toxicity versus pembrolizumab monotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer who had a PD-L1 tumor proportion score of 50% or greater, and did not harbor EGFR or ALK aberrations.
Mobocertinib Shows Encouraging ORR in EGFR Exon 20–Mutant Advanced NSCLC
January 30th 2021January 29, 2021 — Mobocertinib (formerly TAK-788) demonstrated clinically meaningful benefit and a manageable safety profile in previously treated patients with metastatic non–small cell lung cancer who have EGFR exon 20 insertion mutations.
Datopotamab Deruxtecan Elicits Early Antitumor Activity in Relapsed/Refractory Metastatic NSCLC
January 29th 2021January 29, 2021 - The investigational antibody-drug conjugate datopotamab deruxtecan demonstrated encouraging antitumor activity and a manageable safety profile in patients with advanced or metastatic non–small cell lung cancer.
Patritumab Deruxtecan Displays Promising Efficacy in EGFR-Mutant NSCLC
January 29th 2021January 29, 2021 - The HER3-directed antibody-drug conjugate patritumab deruxtecan continued to demonstrate clinically meaningful antitumor activity and a manageable safety profile at the recommended expansion dose of 5.6 mg/kg in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer.
Adjuvant Osimertinib Extends DFS Irrespective of Prior Adjuvant Chemo in EGFR+ NSCLC
January 29, 2021 - Adjuvant osimertinib was found to improve disease-free survival in patients with EGFR-mutated non–small cell lung cancer, irrespective of previous adjuvant chemotherapy received or disease stage.
Trastuzumab Deruxtecan Shows Antitumor Activity in HER2-Overexpressing NSCLC
January 29, 2021 - The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki demonstrated antitumor activity in patients with HER2-overexpressing non–small cell lung cancer, irrespective of expression levels.
Nab-Paclitaxel Noninferior to Docetaxel in Previously Treated NSCLC
January 29th 2021January 29, 2021 - Nab-paclitaxel proved to be noninferior to docetaxel, having showcased improved progression-free survival, overall survival, and overall response rate in patients with previously treated advanced non–small cell lung cancer.
Bemcentinib Plus Pembrolizumab Shows Clinical Activity in Advanced NSCLC
January 29th 2021January 29, 2021 - The first-in-class oral kinase inhibitor bemcentinib, when used in combination with pembrolizumab, demonstrated clinical activity with favorable tolerability in patients with checkpoint inhibitor–naïve and CPI-refractory composite AXL–positive non–small cell lung cancer.
Dr. Sabari on the Updated Results of the CHRYSALIS Study With Amivantamab in EGFR+ NSCLC
January 29th 2021Joshua K. Sabari, MD, discusses updated results from the phase 1 CHRYSALIS trial examining amivantamab in patients with non–small cell lung cancer whose tumors harbored EGFR exon 19 deletion or L858R mutations.
Sotorasib Elicits Rapid Responses, Encouraging PFS in Advanced KRAS G12C+ NSCLC
January 28, 2021 - Treatment with the KRAS G12C inhibitor sotorasib (formerly AMG 510) elicited a 6.8-month median progression-free survival in patients with KRAS G12C–mutated advanced non–small cell lung cancer.
NeoADAURA Trial Slated to Examine Neoadjuvant Osimertinib in Resectable EGFR+ NSCLC
January 28th 2021January 28, 2021 - The NeoADAURA trial will evaluate the safety and efficacy of neoadjuvant osimertinib, as a single agent or in combination with platinum-based chemotherapy compared with chemotherapy alone, in patients with resectable, stage II-IIIB non–small cell lung cancer whose tumors harbor EGFR mutations.